Fear over NICE guidance on prostate cancer drug

It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence.  Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.

The pharmaletter.